Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach

AIMS: To investigate the impact on weight loss of the treatment changes in overweight or obese people that may be needed in case of gastrointestinal (GI) tolerability issues during escalation of the glucagon‐like peptide‐1 analogue liraglutide. MATERIALS AND METHODS: The individual longitudinal body...

Descripción completa

Detalles Bibliográficos
Autores principales: Papathanasiou, Theodoros, Strathe, Anders, Agersø, Henrik, Lund, Trine Meldgaard, Overgaard, Rune Viig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317899/
https://www.ncbi.nlm.nih.gov/pubmed/32009288
http://dx.doi.org/10.1111/dom.13985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317899/
https://www.ncbi.nlm.nih.gov/pubmed/32009288
http://dx.doi.org/10.1111/dom.13985

Ejemplares similares